Morgan Stanley Issues Positive Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target hoisted by stock analysts at Morgan Stanley from $758.00 to $779.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has an “equal weight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s target price points to a potential upside of 4.21% from the stock’s current price.

A number of other brokerages also recently weighed in on REGN. Citigroup boosted their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the company a “neutral” rating in a report on Monday, August 3rd. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Sunday, September 20th. Jefferies Financial Group boosted their target price on shares of Regeneron Pharmaceuticals from $870.00 to $930.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. Piper Sandler dropped their target price on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating on the stock in a report on Thursday, July 9th. Finally, Wells Fargo & Company raised their price target on shares of Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $814.54.

Regeneron Pharmaceuticals Stock Up 1.2%

Shares of REGN stock traded up $8.84 during trading hours on Wednesday, hitting $747.56. 131,556 shares of the company were exchanged, compared to its average volume of 825,125. The stock has a market capitalization of $76.97 billion, a price-to-earnings ratio of 18.46, a P/E/G ratio of 1.39 and a beta of 0.16. Regeneron Pharmaceuticals has a one year low of $541.00 and a one year high of $859.34. The business’s 50-day simple moving average is $790.36 and its two-hundred day simple moving average is $720.41. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.78 and a current ratio of 3.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, beating the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same period in the previous year, the company earned $12.81 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 16.7% on a year-over-year basis. Sell-side analysts predict that Regeneron Pharmaceuticals will post 45.37 EPS for the current fiscal year.

Insider Activity at Regeneron Pharmaceuticals

In other news, Director Huda Y. Zoghbi sold 800 shares of the business’s stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total transaction of $640,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. The trade was a 31.96% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marion Mccourt sold 1,215 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $1,032,750.00. Following the transaction, the executive vice president owned 13,134 shares of the company’s stock, valued at $11,163,900. This represents a 8.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,946 shares of company stock worth $3,302,458 in the last 90 days. 6.97% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of REGN. Central Pacific Bank Trust Division grew its position in Regeneron Pharmaceuticals by 90.3% in the 3rd quarter. Central Pacific Bank Trust Division now owns 2,687 shares of the biopharmaceutical company’s stock worth $2,037,000 after purchasing an additional 1,275 shares during the last quarter. Baker Tilly Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.6% during the third quarter. Baker Tilly Wealth Management LLC now owns 1,461 shares of the biopharmaceutical company’s stock valued at $1,108,000 after buying an additional 51 shares during the last quarter. Eastern Bank raised its holdings in shares of Regeneron Pharmaceuticals by 31.6% during the third quarter. Eastern Bank now owns 75 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 18 shares during the last quarter. CX Institutional boosted its position in shares of Regeneron Pharmaceuticals by 30.1% during the third quarter. CX Institutional now owns 501 shares of the biopharmaceutical company’s stock worth $380,000 after buying an additional 116 shares during the period. Finally, Versant Capital Management Inc boosted its position in shares of Regeneron Pharmaceuticals by 55.2% during the third quarter. Versant Capital Management Inc now owns 534 shares of the biopharmaceutical company’s stock worth $405,000 after buying an additional 190 shares during the period. 83.31% of the stock is owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.